BI-1181181
- Generic Name
- BI-1181181
Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin
Phase 1
Withdrawn
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02345304
- Locations
- 🇩🇪
1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 1181181, RDrug: BI 1181181, T2Drug: Placebo to BI 1181181Drug: BI 1181181, T1
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT02044406
- Locations
- 🇩🇪
1344.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath